Mitochondrial-derived peptide (metabolic exercise mimetic research)
Mitochondrial open reading frame peptide
A mitochondrial-encoded peptide studied for metabolic and exercise-mimetic effects; human evidence remains emerging and limited.
- Evidence:
- Early-stage human research
- Status:
- Research-stage
- Reviewed:
- 2026-08-03
Also known as: Mitochondrial open reading frame peptide
What is Mitochondrial open reading frame peptide?
A mitochondrial-encoded peptide studied for metabolic and exercise-mimetic effects; human evidence remains emerging and limited.
This profile is educational. It organizes publicly discussed research context for Mitochondrial open reading frame peptide and related naming aliases — it is not a treatment guide.
Proposed mechanism
Activates AMPK and regulates nuclear gene expression related to glucose and fatty acid metabolism; proposed exercise-mimetic effects.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Early-stage human research
Preclinical evidence grade: Moderate human evidence
MOTS-c is endogenously produced and declines with age in some studies. Animal models show improved insulin sensitivity and exercise capacity. Early human studies explore metabolic effects in sedentary adults. Available evidence suggests biological plausibility but human evidence remains limited. Frequently discussed in biohacking contexts without robust clinical validation.
Key uncertainties
- Clinical efficacy in humans
- Optimal research contexts
Research areas being studied
- Metabolic syndrome
- Exercise physiology
- Aging research
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Insufficient systematic human AE reporting
Additional risks & considerations
- Limited human safety data
- Unregulated product variability
- Unknown long-term effects
Regulatory status
Research-stage
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is Mitochondrial open reading frame peptide?
A mitochondrial-encoded peptide studied for metabolic and exercise-mimetic effects; human evidence remains emerging and limited.
How does Mitochondrial open reading frame peptide work (proposed mechanism)?
Activates AMPK and regulates nuclear gene expression related to glucose and fatty acid metabolism; proposed exercise-mimetic effects.
What is Mitochondrial open reading frame peptide being researched for?
Mitochondrial open reading frame peptide has been discussed in research contexts including: Metabolic syndrome, Exercise physiology, Aging research.
What does current evidence say about Mitochondrial open reading frame peptide?
Early-stage human research. MOTS-c is endogenously produced and declines with age in some studies. Animal models show improved insulin sensitivity and exercise capacity. Early human studies explore metabolic effects in sedentary adults. Available evidence suggests biological plausibility but human evidence remains limited. Frequently discussed in biohacking contexts without robust clinical validation.
What safety considerations are noted for Mitochondrial open reading frame peptide?
Reported or discussed considerations include: Insufficient systematic human AE reporting; Limited human safety data; Unregulated product variability; Unknown long-term effects. This is educational information, not medical advice.
References & sources
- Lee C et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis — Cell Metab. Evidence type: animal.
Prefer interactive tools? Open the PepGuide library entry for Mitochondrial open reading frame peptide or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.